High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients

被引：0
|
作者：
Vaccaro, A.
Ciancola, F.
Pizzuti, L.
Sperduti, I.
Moscetti, L.
Vici, P.
Longo, F.
Ruggeri, E.
Di Seri, M.
Giampaolo, M. A.
Gamucci, T.
机构：
[1] Med Oncol Unit ASL Frosinone, Frosinone, Italy
[2] Policlin Umberto 1, Rome, Italy
[3] Regina Elena Inst Canc Res, Rome, Italy
[4] UOC Oncol Presidio Osped Centrale Belcolle AUSL, Viterbo, Italy
[5] Belcolle Hosp, Viterbo, Italy
[6] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.609
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
609
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer
    Gorshein, Elan
    Klein, Paula
    Boolbol, Susan K.
    Shao, Theresa
    CLINICAL BREAST CANCER, 2014, 14 (05) : 309 - 314
  • [2] High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers
    Akiyo Horio
    Takashi Fujita
    Hironori Hayashi
    Masaya Hattori
    Naoto Kondou
    Mai Yamada
    Eri Adachi
    Aya Ushio
    Naomi Gondou
    Aiko Sueta
    Yasushi Yatabe
    Hiroji Iwata
    International Journal of Clinical Oncology, 2012, 17 : 131 - 136
  • [3] High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers
    Horio, Akiyo
    Fujita, Takashi
    Hayashi, Hironori
    Hattori, Masaya
    Kondou, Naoto
    Yamada, Mai
    Adachi, Eri
    Ushio, Aya
    Gondou, Naomi
    Sueta, Aiko
    Yatabe, Yasushi
    Iwata, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (02) : 131 - 136
  • [4] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [5] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer
    Oguz, Arzu
    Keskin, Gul Sema
    Colak, Dilsen
    Altundag, Ozden
    Akcali, Zafer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 639 - +
  • [6] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    Tolaney, Sara M.
    Barry, William T.
    Dang, Chau T.
    Yardley, Denise A.
    Moy, Beverly
    Marcom, P. Kelly
    Albain, Kathy S.
    Rugo, Hope S.
    Ellis, Matthew
    Shapira, Iuliana
    Wolff, Antonio C.
    Carey, Lisa A.
    Overmoyer, Beth A.
    Partridge, Ann H.
    Guo, Hao
    Hudis, Clifford A.
    Krop, Ian E.
    Burstein, Harold J.
    Winer, Eric P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 134 - 141
  • [7] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    Cochereau, D.
    Cottu, P.
    ONCOLOGIE, 2015, 17 (04) : 194 - 196
  • [8] Updates in HER2-Positive and Triple-Negative Breast Cancers
    Telli, Melinda L.
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 605 - 609
  • [9] TRIPLE-NEGATIVE OR HER2-POSITIVE STATUS PREDICTS HIGHER RATES OF LOCOREGIONAL RECURRENCE IN NODE-POSITIVE BREAST CANCER PATIENTS AFTER MASTECTOMY
    Wang, Shu-Lian
    Li, Ye-Xiong
    Song, Yong-Wen
    Wang, Wei-Hu
    Jin, Jing
    Liu, Yue-Ping
    Liu, Xin-Fan
    Yu, Zi-Hao
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1095 - 1101
  • [10] The evolution in management of patients with subcentimeter, node-negative, triple-negative breast cancer
    Wolfe, Emily
    Corsetti, Ralph
    Bolton, John S.
    Stolier, Alan J.
    Fuhrman, George M.
    AMERICAN JOURNAL OF SURGERY, 2013, 206 (06): : 888 - 892
12345